Gilead Sciences CEO on delivering transformative medicines, company evolutionThe career of Gilead Sciences’ chairman and CEO Daniel O’Day has allowed him to contribute to significant medical advances for some of the world’s most challenging diseases. In 2019, after more than three decades at Roche and Genentech, O’Day took the helm at Gilead Sciences. Headquartered in Foster City, Gilead is a global company with more than 17,000 employees.
Gilead has been headquartered in Foster City for 35 years. How has the company’s time in the Bay Area benefitted the region? After becoming CEO of Gilead in 2019, you laid out a vision for transforming the company. Talk about how Gilead has evolved since then. You recently announced the development of a new research center on your campus. How will this enable future innovation?
We know that our therapies will have the greatest impact if we can help break down barriers to care. Gilead partners with multiple community-based organizations that aim to address stigma, discrimination and other factors that stand in the way of health equity. Through the Gilead Foundation, we focus on social, economic and environmental factors that impact well-being and, here in the Bay area, we support a number of organizations that focus on equity in our schools.
الإمارات العربية المتحدة أحدث الأخبار, الإمارات العربية المتحدة عناوين
Similar News:يمكنك أيضًا قراءة قصص إخبارية مشابهة لهذه التي قمنا بجمعها من مصادر إخبارية أخرى.
مصدر: SFBusinessTimes - 🏆 78. / 68 اقرأ أكثر »
مصدر: SFBusinessTimes - 🏆 78. / 68 اقرأ أكثر »